Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism

J Nanobiotechnology. 2011 Sep 19;9:40. doi: 10.1186/1477-3155-9-40.

Abstract

Background: The development of effective drug delivery systems capable of transporting small interfering RNA (siRNA) has been elusive. We have previously reported that colorectal cancer tumor xenograft growth was arrested following treatment with liposomal preparation of siDCAMKL-1. In this report, we have utilized Nanoparticle (NP) technology to deliver DCAMKL-1 specific siRNA to knockdown potential key cancer regulators. In this study, mRNA/miRNA were analyzed using real-time RT-PCR and protein by western blot/immunohistochemistry. siDCAMKL-1 was encapsulated in Poly(lactide-co-glycolide)-based NPs (NP-siDCAMKL-1); Tumor xenografts were generated in nude mice, treated with NP-siDCAMKL-1 and DAPT (γ-secretase inhibitor) alone and in combination. To measure let-7a and miR-144 expression in vitro, HCT116 cells were transfected with plasmids encoding the firefly luciferase gene with let-7a and miR-144 miRNA binding sites in the 3'UTR.

Results: Administration of NP-siDCAMKL-1 into HCT116 xenografts resulted in tumor growth arrest, downregulation of proto-oncogene c-Myc and Notch-1 via let-7a and miR-144 miRNA-dependent mechanisms, respectively. A corresponding reduction in let-7a and miR-144 specific luciferase activity was observed in vitro. Moreover, an upregulation of EMT inhibitor miR-200a and downregulation of the EMT-associated transcription factors ZEB1, ZEB2, Snail and Slug were observed in vivo. Lastly, DAPT-mediated inhibition of Notch-1 resulted in HCT116 tumor growth arrest and down regulation of Notch-1 via a miR-144 dependent mechanism.

Conclusions: These findings demonstrate that nanoparticle-based delivery of siRNAs directed at critical targets such as DCAMKL-1 may provide a novel approach to treat cancer through the regulation of endogenous miRNAs.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Carcinoma / drug therapy*
  • Colorectal Neoplasms / drug therapy*
  • Dipeptides / pharmacology
  • Down-Regulation
  • Gene Expression Regulation, Neoplastic / drug effects
  • HCT116 Cells
  • Humans
  • Intracellular Signaling Peptides and Proteins / pharmacology*
  • Mice
  • Mice, Nude
  • MicroRNAs / metabolism*
  • Nanoparticles / administration & dosage*
  • Protein-Serine-Threonine Kinases / pharmacology*
  • Proto-Oncogene Proteins c-myc / metabolism
  • Receptor, Notch1 / metabolism*
  • Transcription Factors / metabolism
  • Up-Regulation
  • Xenograft Model Antitumor Assays

Substances

  • Dipeptides
  • Intracellular Signaling Peptides and Proteins
  • MIRN144 microRNA, human
  • MIRN200 microRNA, human
  • MYC protein, human
  • MicroRNAs
  • N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester
  • NOTCH1 protein, human
  • Proto-Oncogene Proteins c-myc
  • Receptor, Notch1
  • Transcription Factors
  • mirnlet7 microRNA, human
  • DCLK1 protein, human
  • Protein-Serine-Threonine Kinases